Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models
Figure 3.Exenatide reduces ER stress and the activation of NF-κB signaling pathway. (A–C) qPCR assay for ATF6, IRE1 and PERK transcription. (D) ELISA assay for NF-κB activity. (E–F) Immunofluorescence staining for NF-κB. *P<0.05.